Temporal trends in liver-directed therapy of patients with intrahepatic cholangiocarcinoma in the United States: A population-based analysis

Journal of Surgical Oncology

Volumn 110, Issue 2, 2014, Pages 163-170

  Amini, Neda ^a,b   Ejaz, Aslam ^a   Spolverato, Gaya ^a   Kim, Yuhree ^a   Herman, Joseph M ^a   Pawlik, Timothy M ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

cholangiocarcinoma; intrahepatic; liver directed; outcome; population based

Indexed keywords

ANTINEOPLASTIC AGENT;

ABLATION THERAPY; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURGERY; CONTROLLED STUDY; DISTANT METASTASIS; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; LIVER; LIVER RESECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; RISK FACTOR; TREND STUDY; TUMOR VOLUME; UNITED STATES;

CHOLANGIOCARCINOMA; INTRAHEPATIC; LIVER-DIRECTED; OUTCOME; POPULATION-BASED;

ABLATION TECHNIQUES; ADULT; AGED; AGED, 80 AND OVER; CHOLANGIOCARCINOMA; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RADIOTHERAPY; RETROSPECTIVE STUDIES; SEER PROGRAM; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 84904071198     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23605     Document Type: Article

References (50)

1. Bektas H, Schrem H, Kleine M, et al.: Primary liver tumours-Presentation, diagnosis and surgical treatment. In Helen Reeves DMMaRL,editor. Liver Tumors-Epidemiology, Diagnosis, Prevention and Treatment. InTech 2013; 91-116.
2. Chang K-Y, Chang J-Y, Yen Y,: Increasing incidence of intrahepatic cholangiocarcinoma and its relationship to chronic viral hepatitis. J Natl Compr Cancer Netw 2009; 7: 423-427.
3. Bertuccio P, Bosetti C, Levi F, et al.: A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe. Ann Oncol 2013; 24: 1667-1674.
4. Reddy S, Hyder O, Marsh JW, et al.: Prevalence of nonalcoholic steatohepatitis among patients with resectable intrahepatic cholangiocarcinoma. J Gastrointest Surg 2013; 17: 748-755.
5. Khan SA, Thomas HC, Davidson BR, et al.: Cholangiocarcinoma. Lancet 2005; 366: 1303-1314. (Pubitemid 41416587)
6. Dhanasekaran R, Hemming A, Zendejas I, et al.: Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma. Oncol Rep 2013; 29: 1259-1267.
7. Liu ZH, Chen Z, Ma LL, et al.: Factors influencing the prognosis of patients with intrahepatic cholangiocarcinoma. Acta Gastroenterol Belg 2012; 75: 215-218.
8. Scheuermann U, Kaths JM, Heise M, et al.: Comparison of resection and transarterial chemoembolisation in the treatment of advanced intrahepatic cholangiocarcinoma-A single-center experience. Eur J Surg Oncol (EJSO) 2013; 39: 593-600.
9. Lang H, Sotiropoulos GC, Sgourakis G, et al.: Operations for intrahepatic cholangiocarcinoma: Single-institution experience of 158 patients. J Am Coll Surg 2009; 208: 218-228.
10. Hyder O, Marsh JW, Salem R, et al.: Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: A multi-institutional analysis. Ann Surg Oncol 2013.
11. de Jong MC, Nathan H, Sotiropoulos GC, et al.: Intrahepatic cholangiocarcinoma: An international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol 2011; 29: 3140-3145.
12. Ribero D, Pinna AD, Guglielmi A, et al.: Surgical approach for long-term survival of patients with intrahepatic cholangiocarcinoma: A multi-institutional analysis of 434 patientssurgery for intrahepatic cholangiocarcinoma. Arch Surg 2012; 147: 1107-1113.
13. de Jong MC, Marques H, Clary BM, et al.: The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: A multi-institutional analysis of 305 cases. Cancer 2012; 118: 4737-4747.
14. Hyder O, Hatzaras I, Sotiropoulos GC, et al.: Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery 2013; 153: 811-818.
15. Sriputtha S, Khuntikeo N, Promthet S, et al.: Survival rate of intrahepatic cholangiocarcinoma patients after surgical treatment in Thailand. Asian Pac J Cancer Prev 2013; 14: 1107-1110.
16. Arrington AK, Nelson RA, Falor A, et al.: Impact of medical and surgical intervention on survival in patients with cholangiocarcinoma. World J Gastrointest Surg 2013; 5: 178-186.
17. Guglielmi A, Ruzzenente A, Campagnaro T, et al.: Intrahepatic cholangiocarcinoma: Prognostic factors after surgical resection. World J Surg 2009; 33: 1247-1254.
18. Choi S-B, Kim K-S, Choi J-Y, et al.: The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: Association of lymph node metastasis and lymph node dissection with survival. Ann Surg Oncol 2009; 16: 3048-3056.
19. Maithel SK, Gamblin TC, Kamel I, et al.: Multidisciplinary approaches to intrahepatic cholangiocarcinoma. Cancer 2013; p. n/a-n/a.
20. Endo I, Gonen M, Yopp AC, et al.: Intrahepatic cholangiocarcinoma: Rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 2008; 248: 84-96.
21. Shinohara ET, Mitra N, Guo M, et al.: Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 2008; 72: 1495-1501.
22. Nathan H, Pawlik TM, Wolfgang CL, et al.: Trends in survival after surgery for cholangiocarcinoma: A 30-year population-based SEER database analysis. J Gastrointest Surg 2007; 11: 1488-1496; discussion 1496-1497.
23. Asiyanbola B, Chang D, Gleisner A, et al.: Operative mortality after hepatic resection: Are literature-based rates broadly applicable ? J Gastrointest Surg 2008; 12: 842-851.
24. The Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER Stat Database: Incidence-SEER 9 Regs Research Data, Nov 2011 Sub (1973-2010). To County Attributes-Total U.S., 1969-2010 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2013, based on the November 2012 submission.
25. Kaplan EL, Meier P,: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
26. Cox DR,: Regression models and life-tables. J R Stat Soc B 1972; 187-220.
27. Hosmer DW, Jr., Lemeshow S, May S,: Applied survival analysis: Regression modeling of time to event data, Vol. 618. Hoboken, NJ, USA: John Wiley & Sons Inc; 2011.
28. Shaib YH, Davila JA, McGlynn K, et al.: Rising incidence of intrahepatic cholangiocarcinoma in the United States: A true increase ? J Hepatol 2004; 40: 472-477. (Pubitemid 38230849)
29. Dodson RM, Weiss MJ, Cosgrove D, et al.: Intrahepatic cholangiocarcinoma: Management options and emerging therapies. J Am Coll Surg 2013; 217: 736.e4-750.e4.
30. Patel T,: Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33: 1353-1357. (Pubitemid 32496970)
31. Tan JC, Coburn NG, Baxter NN, et al.: Surgical management of intrahepatic cholangiocarcinoma-A population-based study. Ann Surg Oncol 2008; 15: 600-608.
32. Nathan H, Aloia TA, Vauthey J-N, et al.: A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol 2009; 16: 14-22.
33. Lang H, Sotiropoulos GC, Frühauf NR, et al.: Extended hepatectomy for intrahepatic cholangiocellular carcinoma (ICC): When is it worthwhile? Single center experience with 27 resections in 50 patients over a 5-year period. Ann Surg 2005; 241: 134.
34. Puhalla H, Schuell B, Pokorny H, et al.: Treatment and outcome of intrahepatic cholangiocellular carcinoma. Am J Surg 2005; 189: 173-177. (Pubitemid 40255107)
35. Guglielmi A, Ruzzenente A, Campagnaro T, et al.: Patterns and prognostic significance of lymph node dissection for surgical treatment of perihilar and intrahepatic cholangiocarcinoma. J Gastrointest Surg 2013; 17: 1917-1928.
36. Uchiyama K, Yamamoto M, Yamaue H, et al.: Impact of nodal involvement on surgical outcomes of intrahepatic cholangiocarcinoma: A multicenter analysis by the Study Group for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 2011; 18: 443-452.
37. Wadsworth CA, Westaby D, Khan SA,: Endoscopic radiofrequency ablation for cholangiocarcinoma. Curr Opin Gastroenterol 2013; 29: 305-311.
38. Xu H, Wang Y, Lu M, et al.: Percutaneous ultrasound-guided thermal ablation for intrahepatic cholangiocarcinoma. Br J Radiol 2012; 85: 1078-1084.
39. Kim JH, Won HJ, Shin YM, et al.: Radiofrequency ablation for recurrent intrahepatic cholangiocarcinoma after curative resection. Eur J Radiol 2011; 80: e221-e225.
40. Xu HX, Lu MD, Xie XY, et al.: Prognostic factors for long-term outcome after percutaneous thermal ablation for hepatocellular carcinoma: A survival analysis of 137 consecutive patients. Clin Radiol 2005; 60: 1018-1025. (Pubitemid 41194673)
41. Bruix J, Sherman M,: Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236. (Pubitemid 43112690)
42. Hammill CW, Billingsley KG, Cassera MA, et al.: Outcome after laparoscopic radiofrequency ablation of technically resectable colorectal liver metastases. Ann Surg Oncol 2011; 18: 1947-1954.
43. Norlén O, Stålberg P, Zedenius J, et al.: Outcome after resection and radiofrequency ablation of liver metastases from small intestinal neuroendocrine tumours. Br J Surg 2013; 100: 1505-1514.
44. Fu Y, Yang W, Wu W, et al.: Radiofrequency ablation in the management of unresectable intrahepatic cholangiocarcinoma. J Vasc Interv Radiol 2012; 23: 642-649.
45. Chen Y-X, Zeng Z-C, Tang Z-Y, et al.: Determining the role of external beam radiotherapy in unresectable intrahepatic cholangiocarcinoma: A retrospective analysis of 84 patients. BMC Cancer 2010; 10: 492.
46. Zeng ZC, Tang ZY, Fan J, et al.: Consideration of the role of radiotherapy for unresectable intrahepatic cholangiocarcinoma: A retrospective analysis of 75 patients. Cancer J 2006; 12: 113-122.
47. Valle J, Wasan H, Palmer DH, et al.: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273-1281.
48. Okusaka T, Nakachi K, Fukutomi A, et al.: Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: A comparative multicentre study in Japan. Br J Cancer 2010; 103: 469-474.
49. Murakami Y, Uemura K, Sudo T, et al.: Adjuvant chemotherapy with gemcitabine and S-1 after surgical resection for advanced biliary carcinoma: Outcomes and prognostic factors. J Hepatobiliary Pancreat Sci 2012; 19: 306-313.
50. Field R, Smith B, Platz C, et al.: Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review. J Natl Cancer Inst 2004; 96: 1105-1107. (Pubitemid 39172413)